Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
St. Jude Medical’s Durata implantable cardiac defibrillator leads should be “relatively immune” to the problems that led to a recall for the medical device company’s Riata ICD leads, according to a cardiologist who helped bring the Riata problems to light.
Echo Therapeutics initiates discussions with the FDA on the regulatory pathway for its Symphony non-invasive, wireless continuous glucose monitor.
Covidien’s spinout of its Mallinckrodt pharmaceuticals business is slated to close later this month.
Concerns that the medical device tax will push companies to lay off workers and move operations overseas are ‘horse hockey,’ according to consultant Mark Bonifacio.
CareFusion seems to be a key potential acquirer for at least 2 medical device businesses known to be on the block – ICU Medical and Smiths Group’s Smiths Medical.
Study results revealed in Europe this week cast doubt on the efficacy of renal denervation for treating high blood pressure.
A pair of independent analyses of patient-level data commissioned by a Yale University open data program show that Medtronic’s Infuse bone-growth putty is equivalent to bone grafts, with 1 concluding that early Infuse research was biased.